Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
KalVista Pharmaceuticals (NASDAQ: KALV) has completed its Phase 1 clinical trial for an orally disintegrating tablet formulation of sebetralstat, with promising results published in the Journal of Medicinal Chemistry and Xenobiotica. Despite terminating the Phase 2 KOMPLETE trial for KVD824 due to safety concerns, the company remains focused on advancing its Phase 3 KONFIDENT trial for sebetralstat, expecting data in H2 2023. Financially, KALV recorded no revenue for Q2, with a net loss of $22.3 million. Cash on hand is $122.3 million, down from $166.2 million, primarily due to operating expenses.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the granting of inducement stock options for 2,000 shares to a newly-hired employee, effective December 1, 2022. The options have an exercise price of $5.34, matching the closing stock price on the grant date. Vesting occurs in stages, with a quarter vesting after one year and the remainder in monthly installments over three years. KalVista focuses on developing innovative therapies for conditions like hereditary angioedema and diabetic macular edema, with ongoing clinical trials for sebetralstat and KVD001.
KalVista Pharmaceuticals (NASDAQ: KALV) presented two impactful posters at the 2022 American College of Allergy, Asthma & Immunology meeting, revealing the significant effects of hereditary angioedema (HAE) attacks on patients' mental health and daily activities. Over half of HAE patients reported limitations in functions due to the condition. The second poster highlighted the treatment burden related to on-demand parenteral therapies, noting common adverse drug reactions. CEO Andrew Crockett emphasized the need for less traumatic treatment options, leading to KalVista’s focus on developing oral therapies for HAE.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced participation in investor conferences, including the Stifel 2022 Healthcare Conference on November 15, 2022, and the Jefferies London Healthcare Conference on November 17, 2022. Live webcasts of both presentations will be accessible on KalVista's website, with an audio archive available for 30 days post-event. KalVista focuses on developing oral, small molecule protease inhibitors for conditions like hereditary angioedema (HAE) and diabetic macular edema (DME), with ongoing clinical trials for its lead candidate, sebetralstat.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of inducement stock options to a newly hired employee. A total of 2,000 shares were issued at an exercise price of $5.10 per share, equivalent to the closing price on November 1, 2022. The options will vest over four years, with 25% vesting after one year and the remainder in monthly increments. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the new employee's ongoing contribution to the company.
KalVista Pharmaceuticals (NASDAQ: KALV) announced positive Phase 1 results for an orally disintegrating tablet (ODT) formulation of its lead compound, sebetralstat, aimed at treating hereditary angioedema (HAE). The trial involved 36 healthy adult volunteers and indicated a similar pharmacokinetic profile between the ODT and the existing film-coated tablets. The company plans to develop the ODT further and aims for its availability post-launch of sebetralstat. Data from the ongoing Phase 3 KONFIDENT trial is expected in H2 2023, supporting a planned NDA filing in H1 2024.
KalVista Pharmaceuticals announced new data on sebetralstat, published in the Journal of Medicinal Chemistry and Xenobiotica. The research highlights its effectiveness as an on-demand treatment for hereditary angioedema (HAE), showcasing high selectivity against human serine proteases and rapid absorption characteristics, essential for patient needs. Sebetralstat has progressed to Phase 3 KONFIDENT trials, indicating significant advancement towards clinical application. CEO Andrew Crockett expressed optimism about sebetralstat's promise for HAE treatment.
KalVista Pharmaceuticals has announced a significant leadership change, appointing
KalVista Pharmaceuticals presented new data on patient perspectives regarding treatment outcome measures from the phase 3 KONFIDENT trial of sebetralstat at the 2022 HAEi Global Leadership Workshop. The research showed a strong patient preference for using the Patient Global Impression of Change (PGI-C) scale as a clinical endpoint, with over 70% favoring it over other scales. Additionally, findings highlighted the significant mental health impacts of hereditary angioedema (HAE) on patients, with many missing important life events due to anxiety linked to their condition.
KalVista Pharmaceuticals (NASDAQ: KALV) is under investigation by Holzer & Holzer, LLC for potential violations of federal securities laws. This follows the termination of its KOMPLETE phase 2 clinical trial for KVD824 on October 4, 2022, due to elevated liver enzymes observed in all treatment groups. This announcement resulted in a drop in the company's stock price. Investors who incurred losses on their KalVista stock are encouraged to contact Holzer & Holzer for legal advice regarding their rights.
FAQ
What is the current stock price of Kalvista Pharm (KALV)?
What is the market cap of Kalvista Pharm (KALV)?
